GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTPW) » Definitions » EV-to-EBITDA

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) EV-to-EBITDA : 0.00 (As of May. 27, 2024)


View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, 60 Degrees Pharmaceuticals's enterprise value is $0.00 Mil. 60 Degrees Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $0.46 Mil. Therefore, 60 Degrees Pharmaceuticals's EV-to-EBITDA for today is 0.00.

The historical rank and industry rank for 60 Degrees Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

SXTPW' s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.61   Med: -6.56   Max: 281.18
Current: 24.05

During the past 4 years, the highest EV-to-EBITDA of 60 Degrees Pharmaceuticals was 281.18. The lowest was -10.61. And the median was -6.56.

SXTPW's EV-to-EBITDA is ranked worse than
74% of 450 companies
in the Biotechnology industry
Industry Median: 9.57 vs SXTPW: 24.05

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-27), 60 Degrees Pharmaceuticals's stock price is $0.0751. 60 Degrees Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.000. Therefore, 60 Degrees Pharmaceuticals's PE Ratio for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


60 Degrees Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for 60 Degrees Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

60 Degrees Pharmaceuticals EV-to-EBITDA Chart

60 Degrees Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- - - -9.63

60 Degrees Pharmaceuticals Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 257.06 -9.63 22.23

Competitive Comparison of 60 Degrees Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


60 Degrees Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where 60 Degrees Pharmaceuticals's EV-to-EBITDA falls into.



60 Degrees Pharmaceuticals EV-to-EBITDA Calculation

60 Degrees Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=0.000/0.455
=0.00

60 Degrees Pharmaceuticals's current Enterprise Value is $0.00 Mil.
60 Degrees Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


60 Degrees Pharmaceuticals  (NAS:SXTPW) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

60 Degrees Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0751/0.000
=N/A

60 Degrees Pharmaceuticals's share price for today is $0.0751.
60 Degrees Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


60 Degrees Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases through Arakoda and Celgosivir.

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Headlines